NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.
Memorial Hospital Central
Memorial Hospital North
University of Colorado Hospital
Kian Behbakht, MD, MBA
Protocol Number: 18-2281
More information available at ClinicalTrials.gov: NCT03660826
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers